Stockreport

Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review

Theratechnologies Inc. - Common Shares  (THTX) 
PDF Resubmission addresses questions raised in January 2024 Complete Response Letter F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment [Read more]